RA-PRO Pragmatic Trial for Rheumatoid Arthritis
This study is for people with active rheumatoid arthritis (RA) whose current treatment isn't working well. We are comparing two different approaches to changing your medication: switching to a targeted synthetic DMARD (like tofacitinib, baricitinib, or upadacitinib) or switching to a non-TNFi biologic (like rituximab, abatacept, tocilizumab, or sarilumab). The goal is to see which approach leads to better functional ability over 12 months. You may be able to join if you are 18 or older and have active, disabling RA despite using a TNFi-biologic, or if you stopped your previous medication due to side effects. The study aims to enroll 924 participants.
- Study design
- This is an interventional study with a planned enrollment of 924 participants. It compares two different drug classes for treating rheumatoid arthritis.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your functional ability will be measured for 12 months after starting the new treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
RA-PRO PRAGMATIC TRIAL
At a glance
Conditions
Where it's being run
49 sites across 19 statesStudy leadership
- Jasvinder Singh, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Functional LimitationChange from baseline to 12 months
Function limitation assessed by Health assessment questionnaire (HAQ); HAQ assesses difficulty in 20 items in 8 categories (dressing, arising, eating, walking, hygiene, reaching, gripping, and outside activity), the total score ranges from 0 (no disability) to 3 (complete disability). Higher score is worse, and indicates poor function.